N/A
Manufactured by Aurobindo Pharma Limited
18,805 FDA adverse event reports analyzed
Last updated: 2026-04-14
EFAVIRENZ is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for EFAVIRENZ include VIROLOGIC FAILURE, DRUG INTERACTION, DRUG RESISTANCE, VIRAL MUTATION IDENTIFIED, PATHOGEN RESISTANCE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for EFAVIRENZ.
Out of 11,001 classified reports for EFAVIRENZ:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 18,805 FDA FAERS reports that mention EFAVIRENZ. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include VIROLOGIC FAILURE, DRUG INTERACTION, DRUG RESISTANCE, VIRAL MUTATION IDENTIFIED, PATHOGEN RESISTANCE, FOETAL EXPOSURE DURING PREGNANCY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with EFAVIRENZ. Always verify the specific product and NDC with your pharmacist.